In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on LianBio Sponsored ADR (LIAN – Research Report), with a price target of $13.00. The company’s shares closed yesterday at $1.67.
According to TipRanks, Yee is an analyst with an average return of -1.0% and a 44.72% success rate. Yee covers the Healthcare sector, focusing on stocks such as Amgen, Biogen, and Prothena.
LianBio Sponsored ADR has an analyst consensus of Hold.
See the top stocks recommended by analysts >>
LIAN market cap is currently $181M and has a P/E ratio of -1.59.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications.
Read More on LIAN:
- Pfizer opts in to LianBio rights to RSV therapeutic candidate sisunatovir
- Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
- LianBio Announces President and Chief Strategy Officer Departure
- LianBio announces departure of President and Chief Strategy Officer Debra Yu
- LianBio doses 1st patient in Phase 1 of BBP-398 in Chinese patients with tumors
